Role of the retinoblastoma protein in the pathogenesis of human cancer

Journal of Clinical Oncology

Volumn 15, Issue 11, 1997, Pages 3301-3312

  Sellers, William R ^a   Kaelin Jr , William G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOBLASTOMA PROTEIN;

CARCINOGENESIS; GENE MUTATION; HUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; TRANSCRIPTION REGULATION;

EID: 0030678627     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.11.3301     Document Type: Review

References (173)

1. Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823, 1971
2. Knudson AG Jr: Retinoblastoma: A prototypic hereditary neoplasm. Semin Oncol 5:57-60, 1978
3. Godbout R, Dryja TP, Squire J, et al: Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature 304:451-453, 1983
4. Cavenee WK, Dryja TP, Phillips RA, et al: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779-784, 1983
5. Benedict WF, Murphree AL, Banerjee A, et al: Patient with chromosome 13 deletion: Evidence that the retinoblastoma gene is a recessive cancer gene. Science 219:973-975, 1983
6. Sparkes RS, Murphree AL, Lingua RW, et al: Gene for hereditary retinoblastoma assigned to human chromosome 13 by linkage to esterase D. Science 219:971-973, 1983
7. Murphree AL, Benedict WF: Retinoblastoma: Clues to human oncogenesis. Science 223:1028-1033, 1984
8. Friend SH, Bernards R, Rogelj S, et al: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646, 1986
9. Lee W-H, Bookstein R, Hong F, et al: Human retinoblastoma susceptibility gene: Cloning, identification, and sequence. Science 235:1394-1399, 1987
10. Fung Y-KT, Murphree AL, T'Ang A, et al: Structural evidence for the authenticity of the human retinoblastoma gene. Science 236:1657-1661, 1987
11. Goodrich DW, Lee W-H: Molecular characterization of the retinoblastoma susceptibility gene. Biochim Biophys Acta 1155:43-61, 1993
12. Huang H-JS, Yee J-K, Shew J-Y, et al: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563-1566, 1988
13. DeCaprio JA, Ludlow JW, Lynch D, et al: The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58:1085-1095, 1989
14. Buchkovich K, Duffy LA, Harlow E: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58:1097-1105, 1989
15. Chen P, Scully P, Shew J, et al: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58:1193-1198, 1989
16. Mihara K, Cao X, Yen A, et al: Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246:1300-1303, 1989
17. Hinds PW, Mittnacht S, Dulic V, et al: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006, 1992
18. Goodrich DW, Wang NP, Qian Y-W, et al: The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67:293-302, 1991
19. Whyte P, Buchkovich KJ, Horowitz JM, et al: Association between an oncogene and an antioncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334:124-129, 1988
20. DeCaprio JA, Ludlow JW, Figge J, et al: SV40 large T antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-283, 1988
21. Dyson N, Howley PM, Munger K, et al: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937, 1989
22. Hu Q, Dyson N, Harlow E: The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J 9:1147-1155, 1990
23. Kaelin WG, Ewen ME, Livingston DM: Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product. Mol Cell Biol 10:3761-3769, 1990
24. Huang S, Wang N, Tseng BY, et al: Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen. EMBO J 9:1815-1822, 1990
25. Ludlow JW, DeCaprio JA, Huang C, et al: SV40 Large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell 56:57-65, 1989
26. Kaelin WG, Pallas DC, DeCaprio JA, et al: Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell 64:521-532, 1991
27. Taya Y: RB kinases and RB-binding proteins: New points of view. Trends Biochem Sci 21:14-17, 1997
28. Sellers WR, Kaelin WG Jr: RB as a modulator of transcription. Biochem Biophys Acta 1288:M1-M5, 1996
29. Chellappan SP, Hiebert S, Mudryj M, et al: The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053-1061, 1991
30. Bagchi S, Weinmann R, Raychaudhuri P: The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell 65:1063-1072, 1991
31. Chittenden T, Livingston DM, Kaelin WG: The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein. Cell 65:1073-1082, 1991
32. Bandara LR, Adamczewski JP, Hunt T, et al: Cyclin A and the retinoblastoma gene product complex with a common transcription factor. Nature 352:249-251, 1991
33. Shirodkar S, Ewen M, DeCaprio JA, et al: The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 68:157-166, 1992
34. Schwarz JK, Devoto SH, Smith EJ, et al: Interactions of the p107 and Rb proteins with E2F during the cell proliferation response. EMBO J 12:1013-1020, 1993
35. Nevins JR: E2F: A link between the Rb tumor supressor protein and viral oncoproteins. Science 258:424-429, 1992
36. Kovesdi I, Reichel R, Nevins J: Identification of a cellular transcription factor involved in E1A transactivation. Cell 45:219-228, 1986
37. Mudryj M, Hiebert SW, Nevins JR: A role for the adenovirus inducible E2F transcription factor in a proliferation dependent signal transduction pathway. EMBO J 9:2179-2184, 1990
38. La Thangue NB, Rigby PWJ: An Adenovirus E1A-like transcription factor is regulated during the differentiation of murine embryonal carcinoma stem cells. Cell 49:507-513, 1987
39. Adams PD, Kaelin WG: Transcriptional control by E2F. Cancer Biol 6:99-108, 1995
40. La Thangue NB: DRTF1/E2F: An expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem Sci 19:108-114, 1994
41. Ohtani K, DeGregori J, Nevins JR: Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 92:12146-12150, 1995
42. Botz J, Zerfass-Thome K, Spitkovsky D, et al: Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol 16:3401-3409, 1996
43. Geng Y, Eaton EN, Picon M, et al: Regulation of cyclin E transcription by E2Fs and the retinoblastoma protein. Oncogene 12:1173-1180, 1996
44. Johnson DG, Schwarz JK, Cress WD, et al: Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365:349-352, 1993
45. Qin XQ, Livingston DM, Kaelin WG, et al: Deregulated E2F1 Expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 91:10918-10922, 1994
46. Shan B, Lee W-H: Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 14:8166-8173, 1994
47. Johnson D, Cress W, Jakoi L, et al: Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 91:12823-12827, 1994
48. Singh P, Wong S, Hong W: Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 13:3329-3338, 1994
49. Xu G, Livingston D, Krek W: Multiple members of the E2F transcription factor family are the products of oncogenes. Proc Natl Acad Sci USA 92:1357-1361, 1995
50. Dobrowolski SF, Stacey DW, Harter ML, et al: An E2F dominant negative mutant blocks E1A induced cell cycle progression. Oncogene 9:2605-2612, 1994
51. Wu C-L, Classon M, Dyson N, et al: Expression of a dominant-negative mutant DP-1 bloacks cell cycle progression in G1. Mol Cell Biol 16:3968-3706, 1996
52. Duronio RJ, O'Farrel PH, Xie J-E, et al: The transcription factor E2F is required for S phase during Drosophila embryogenesis. Genes Dev 9:1445-1455, 1995
53. Ishizaki J, Nevins JR, Sullenger BA: Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. Nat Med 2:1386-9, 1996
54. Flemington EK, Speck SH, Kaelin WG: E2F-1 mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 90:6914-6918, 1993
55. Hiebert SW, Chellappan SP, Horowitz JM, et al: The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 6:177-185, 1992
56. Helin K, Harlow E, Fattaey A: Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma gene. Mol Cell Biol 13:6501-6508, 1993
57. Weintraub SJ, Prater CA, Dean DC: Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358:259-261, 1992
58. Adnane J, Shao Z, Robbins PD: The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter. J Biol Chem 270:8837-8843, 1995
59. Bremner R, Cohen BL, Sopta M, et al: Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 15:3256-3265, 1995
60. Sellers WR, Rodgers JW, Kaelin Jr. WG: A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc Natl Acad Sci USA 92:11544-11548, 1995
61. Weintraub S, Chow K, Luo R, et al: Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375:812-815, 1995
62. Hiebert SW: Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-Mediated growth suppression. Mol Cell Biol 13:3384-3391, 1993
63. Zhu L, van der Heuvel S, Helin K, et al: Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 7:1111-1125, 1993
64. Qin X-Q, Livingston DM, Ewen M, et al: The transcription factor E2F1 is a downstream target of RB action. Mol Biol Cell 15:742-755, 1995
65. Qin X-Q, Chittenden T, Livingston DM, et al: Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev 6:953-964, 1992
66. Lohmann DR, Brandt B, Hopping W, et al: The spectrum of RB1 germ-line mutations in hereditary retinoblastoma. Am J Hum Genet 58:940-949, 1996
67. Yokota J: Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3:471-475, 1988
68. Mori N, Yokota J, Akiyama T, et al: Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene 5:1713-1717, 1990
69. Hensel CH, Hsieh C-L, Gazdar AF, et al: Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res 30:3067-3072, 1990
70. Harbour JW, Lai S-L, Whang-Peng J, et al: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353-357, 1988
71. Gouyer V, Gazzeri S, Brambilla E, et al: Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas. Int J Cancer 58:818-824, 1994
72. Friend SH, Horowitz JM, Gerber MR, et al: Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci USA 84:9059-9063, 1987
73. Toguchida J, Ishizaki K, Sasaki MS, et al: Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Cancer Res 48:3939-3943, 1988
74. Wunder JS, Czitrom AA, Kandel R, et al: Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl Cancer Inst 83:194-200, 1991
75. Reissmann P, Simon M, Lee W-H, et al: Studies of the retinoblastoma gene in human sarcomas. Oncogene 4:839-843, 1989
76. Wadayama B, Toguchida J, Shimizu T, et al: Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54:3042-3048, 1994
77. T'Ang A, Varley JM, Chakraborty S, et al: Structural rearrangement of the retinoblastoma gene in human breast cancer. Science 242:263-266, 1988
78. Lee EY-H, To H, Shew J-Y, et al: Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218-221, 1989
79. Varley JM, Armour J, Swallow JE, et al: The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene 4:725-729, 1989
80. Miyamoto H, Shuin T, Torigoe S, et al: Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 71:831-835, 1995
81. Cairns P, Proctor AJ, Knowles MA: Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 6:2305-2309, 1991
82. Xu HJ, Cairns P, Hu SX, et al: Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 53:781-784, 1993
83. Ishikawa J, Xu HJ, Hu SX, et al: Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 51:5736-5743, 1991
84. He J, Olson JJ, James CD: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55:4833-4836, 1995
85. Ichimura K, Schmidt EE, Goike HM, et al: Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13:1065-1072, 1996
86. Godbout R, Miyakoshi J, Dobler KD, et al: Lack of expression of tumor-suppressor genes in human malignant glioma cell lines. Oncogene 7:1879-1884, 1992
87. Henson JW, Schnitker BL, Correa KM, et al: The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 36:714-721, 1994
88. Venter DJ, Bevan KL, Ludwig RL, et al: Retinoblastoma gene deletions in human glioblastomas. Oncogene 6:445-448, 1991
89. Ueki K, Ono Y, Henson JW, et al: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153, 1996
90. Sasano H, Comerford J, Silverberg SG, et al: An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. Cancer 66:2150-4, 1990
91. Kim TM, Benedict WF, Xu HJ, et al: Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res 54:605-609, 1994
92. Dodson MK, Cliby WA, Xu HJ, et al: Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res 54:610-613, 1994
93. Liu Y, Heyman M, Wang Y, et al: Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells. Int J Cancer 58:663-667, 1994
94. Li S-b, Schwartz PE, Lee W-H, et al: Allele loss at the retinoblastoma locus in human ovarian cancer. J Natl Cancer Inst 9:637-640, 1991
95. Yoo GH, Xu HJ, Brennan JA, et al: Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res 54:4603-4606, 1994
96. Hawthorn LA, Chapman R, Oscier D, et al: The consistent 13q14 translocation breakpoint seen in chronic B-cell leukaemia (BCLL) involves deletion of the D13S25 locus which lies distal to the retinoblastoma predisposition gene. Oncogene 8:1415-1419, 1993
97. Liu Y, Szekely L, Grander D, et al: Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: Evidence for a role of an adjacent locus. Proc Natl Acad Sci USA 90:8697-8701, 1993
98. Brown AG, Ross FM, Dunne EM, et al: Evidence for a new tumour suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. Nat Genet 3:67-72, 1993
99. Chapman RM, Corcoran MM, Gardiner A, et al: Frequent homozygous deletions of the D13S25 locus in chromosome region 13q14 defines the location of a gene critical in leulaemogenesis in B-cell chronic lymphocytic leukemia. Oncogene 9:1289-1293, 1994
100. Stilgenbauer S, Leupolt E, Ohl S, et al: Heterogeneity of deletions involving RB-1 and the D13S25 locus in B-cell chronic lymphocytic leukemia revealed by fluorescence in situ hybridization. Cancer Res 55:3475-3477, 1995
101. Münger K, Werness BA, Dyson N, et al: Complex formation of human papillomavirus E7 proteins with the retinoblastoma suppressor gene product. EMBO J 8:4099-4105, 1989
102. Saito M, Helin K, Valentine MB, et al: Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics 25:130-138, 1995
103. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
104. Sherr C: Mammalian G1 cyclins. Cell 73:1059-1065, 1993
105. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81:323-330, 1995
106. Kato J-Y, Matsushime H, Hiebert SW, et al: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase cdk4. Genes Dev 7:331-342, 1993
107. Ewen ME, Sluss HK, Sherr CJ, et al: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487-497, 1993
108. Dowdy SF, Hinds PW, Louie K, et al: Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73:499-511, 1993
109. Resnitzky D, Gossen M, Bujard H, Reed SI: Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669-1679, 1994
110. Quelle D, Ashmun RA, Shurtleff SA, et al: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7:1559-1571, 1993
111. Baldin V, Lukas J, Marcote MJ, et al: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7:812-821, 1993
112. Lukas J, Muller H, Bartkova J, et al: DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 125:625-638, 1994
113. Hall M, Peters G: Genetic alterations of cyclins, cyclin-dependent kinases and cdk inhibitors in human cancer. Adv Cancer Res 68:67-108, 1996
114. Motokura T, Bloom T, Kim HG, et al: A novel cyclin encoded by a bell-linked candidate oncogene. Nature 350:512-515, 1991
115. Khatib ZA, Matsushime H, Valentine M, et al: Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53:5535-5541, 1993
116. He J, Allen JR, Collins VP, et al: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54:5804-5807, 1994
117. Wolfel TM, Schneider J, Serrano M, et al: A p16INK4A-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284, 1995
118. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin dependent kinases. Genes Dev 9:1149-1163, 1995
119. Serrano M, Hannon G, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
120. Kamb A, Gruis N, Weaver-Feldhaus J, et al: A cell cylcle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994
121. Nobori T, Miura K, Wu D, et al: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994
122. Koh J, Enders G, Dynlacht B, et al: Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506-510, 1995
123. Guan KL, Jenkins CW, Li Y, et al: Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939-2952, 1994
124. Lukas J, Parry D, Aargaard L, et al: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375:503-506, 1995
125. Medema RH, Herrera RE, Lam F, et al: Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 92:6289-6293, 1995
126. Gonzalez-Zulueta M, Bender CM, Yang AS, et al: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531-4535, 1995
127. Merlo A, Herman JG, Mao L, et al: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers [see comments]. Nat Med 1:686-692, 1995
128. Herman JG, Merlo A, Mao L, et al: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530, 1995
129. Foulkes WD, Flanders TY, Pollock PM, et al: The CDKN2A(p16) gene and human cancer. Mol Med 3:5-21, 1997
130. Strauss M, Lukas J, Bartek J: Unrestricted cell cycling and cancer. Nat Med 1:1245-1246, 1995
131. Otterson GA, Kratzke RA, Coxon A, et al: Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9:3375-3378, 1994
132. Shapiro GI, Edwards CD, Kobzik L, et al: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509, 1995
133. Kelley MJ, Nakagawa K, Steinberg SM, et al: Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst 87:756-761, 1995
134. Zwijsen RML, Wientjens E, Klompmaker J, et al: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88:405-415, 1997
135. Neuman E, Ladha ML, Lin N, et al: Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17:5338-5347, 1997
136. Sicinski P, Donaher JL, Parker SB, et al: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630, 1995
137. Wang T, Cardiff R, Zukerberg L, et al: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 trangenic mice. Nature 369:669-671, 1994
138. Wu X, Levine AJ: p53 and E2F1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91:3602-3606, 1994
139. Howes KA, Ransom N, Papermaster DS, et al: Apoptosis or retinoblastoma: Alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev 8:1300-1310, 1994
140. Morgenbesser SD, Williams BO, Jacks T, et al: p53 dependent apoptosis produced by Rb deficiency in the developing mouse lens. Nature 371:72-74, 1994
141. Jacks T, Fazeli A, Schmitt EM, et al: Effects of an Rb mutation in the mouse. Nature 359:295-300, 1992
142. Lee EY-HP, Chang C-Y, Hu N, et al: Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294, 1992
143. Clarke AR, Maandag ER, van Roon M, et al: Requirement for a functional Rb-1 gene in murine development. Nature 359:328-330, 1992
144. Blanquet V, Turleau C, Gross-Morand MS, et al: Spectrum of germline mutations in the RB1 gene: A study of 232 patients with hereditary and non hereditary retinoblastoma. Hum Mol Genet 4:383-388, 1995
145. Reissmann PT, Koga H, Takahashi R, et al: Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 8:1913-1919, 1993
146. Xu HJ, Hu SX, Cagle PT, et al: Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 51:2735-2739, 1991
147. Juge-Morineau N, Mellerin MP, Francois S, et al: High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 91:664-667, 1995
148. Dao DD, Sawyer JR, Epstein J, et al: Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 8:1280-1284, 1994
149. Zandecki M, Facon T, Preudhomme C, et al: The retinoblastoma gene (RB-1) status in multiple myeloma: A report on 35 cases. Leuk Lymphoma 18:497-503, 1995
150. Niemann TH, Yilmaz AG, McGaughy VR, et al: Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. Gynecol Oncol 65:232-236, 1997
151. Phillips SM, Barton CM, Lee SJ, et al: Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 70:1252-1257, 1994
152. Ittmann MM, Wieczorek R: Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol 27:28-34, 1996
153. Kubota Y, Fujinami K, Uemura H, et al: Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27:314-320, 1995
154. Brooks JD, Bova GS, Isaacs WB: Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 26:35-39, 1995
155. Boynton RF, Huang Y, Blount PL, et al: Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 51:5766-5769, 1991
156. Huang Y, Meltzer SJ, Yin J, et al: Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res 53:1889-1894, 1993
157. Zhang X, Xu HJ, Murakami Y, et al: Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 54:4177-4182, 1994
158. Chen YC, Chen PJ, Yeh SH, et al: Deletion of the human retinoblastoma gene in primary leukemias. Blood 76:2060-2064, 1990
159. Jamal R, Gale RE, Shaun N, et al: The retinoblastoma gene (rb1) in acute myeloid leukaemia: Analysis of gene rearrangements, protein expression and comparison of disease outcome. Br J Haematol 94:342-351, 1996
160. Hangaishi A, Ogawa S, Imamura N, et al: Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 87:4949-4958, 1996
161. Ginsberg AM, Raffeld M, Cossman J: Inactivation of the retinoblastoma gene in human lymphoid neoplasms. Blood 77:833-840, 1991
162. Cho JH, Noguchi M, Ochiai A, et al: Loss of heterozygosity of multiple tumor suppressor genes in human gastric cancers by polymerase chain reaction. Lab Invest 74:835-841, 1996
163. Constancia M, Seruca R, Carneiro F, et al: Retinoblastoma gene structure and product expression in human gastric carcinomas. Br J Cancer 70:1018-1024, 1994 (published erratum appears in Br J Cancer 1995 71:1122)
164. Zhu J, Leon SP, Beggs AH, et al: Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus. J Clin Endocrinol Metab 78:922-927, 1994
165. Woloschak M, Yu A, Xiao J, et al: Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. Int J Cancer 67:16-19, 1996
166. Cryns VL, Alexander JM, Klibanski A, et al: The retinoblastoma gene in human pituitary tumors. J Clin Endocrinol Metab 77:644-646, 1993
167. Lin CT, Chan WY, Chen W, et al: Nasopharyngeal carcinoma and retinoblastoma gene expression. Lab Invest 67:56-70, 1992
168. Sun Y, Hegamyer G, Colburn NH: Nasopharyngeal carcinoma shows no detectable retinoblastoma susceptibility gene alterations. Oncogene 8:791-795, 1993
169. Presti JC Jr, Reuter VE, Cordon-Cardo C, et al: Expression of the retinoblastoma gene product in renal tumors. Anticancer Res 16:549-556, 1996
170. Shuin T, Torigoe S, Kubota Y, et al: Retinoblastoma gene mutation in primary human renal cell carcinoma. Oncol Res 7:63-66, 1995
171. Yamamoto H, Monden T, Ikeda K, et al: Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer. Br J Cancer 71:1231-1236, 1995
172. Barton CM, McKie AB, Hogg A, et al: Abnormalities of the RB1 and DCC tumor suppressor genes: Uncommon in human pancreatic adenocarcinoma. Mol Carcinogen 13:61-69, 1995
173. Parr MJ, Manome Y, Tanaka T, et al: Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral rector. Nature Med 3:1145-1149, 1997